Margherita Fabbri, MD, PhD, University of Toulouse, Toulouse, France, describes the pharmacological and non-pharmacological therapies used for the symptomatic treatment of Parkinson’s disease (PD). Interesting results regarding the use of dopamine D1 receptor agonists in early and late-stage PD are expected soon. Similarly, a low dose of pramipexole with a low dose of rasagiline is a promising therapeutic approach in terms of tolerability. The early use of amantadine can be a helpful strategy to delay motor complications associated with PD, particularly dyskinesia. Physical exercise also plays an important role in improving the gait and motor function of both early and advanced-stage patients. This interview took place at the 2022 International Congress of Parkinson’s disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.